MGMTai: O6-methylguanine-DNA methyltransferase ( MGMT ) methylation prediction in isocitrate dehydrogenase ( IDH )-wild type glioblastoma to direct temozolomide therapy
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 16.04.2026. Verfasst von Patricia Pittman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Caris Life Sciences, Phoenix, Arizona, USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
MGMT promoter methylation status has been utilized as a predictor of response to temozolomide in patients with IDH-wildtype glioblastoma (GBM). Traditional methods of methylation status identification include methylation-specific polymerase chain reaction and pyrosequencing (PyroSeq). Though widely used, each method has disadvantages with respect to determining methylation cut-off values, tumor content required for evaluation, prognostic accuracy, and financial expense.
Methods
We have developed a method of MGMT classification using artificial intelligence and a large clinicogenomic database of 5841 GBM patients. We evaluate the performance of this novel classification strategy for predicting temozolomide treatment efficacy in comparison to PyroSeq techniques.
Results
MGMTai reliably predicted MGMT methylation status in GBM patients with available PyroSeq data. Comparative bucketing of methylation status based on MGMTai and PyroSeq yielded high sensitivity and positive predictive value concordance, though new MGMT promoter methylation (MGMTmet) status percentages were drawn according to PyroSeq methylation percent values. Overall survival with temozolomide (TMZ) treatment was comparable between PyroSeq and MGMTai; however, MGMTai by decile and MGMTai stratified into 3 scoring buckets yielded more distinct and predictive survival patterns with increasing MGMTai score compared to PyroSeq.
Conclusion
Implementation of an AI-based molecular classification system, MGMTai, can better describe MGMT methylation status in comparison to the traditional PyroSeq method. Patient MGMTmet status by MGMTai scoring drew more distinct survival curves and predicted TMZ-treated GBM patient survival more efficiently, less expensively, and with better precision and reproducibility than PyroSeq.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Caris Life Sciences, Phoenix, Arizona, USA.
- Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
- Department of Oncology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
ORCID-Profile: Timothy Samec, Michael Glantz, Theodore Nicolaides
Zitieren
APA
Pittman, P., Sun, C., Samec, T., Davidson, C., Bryant, D., Alnahhas, I., Glantz, M., Hahn-Lowry, R., Spetzler, D., Magee, D., & Nicolaides, T. (2026). MGMTai: O6-methylguanine-DNA methyltransferase ( MGMT ) methylation prediction in isocitrate dehydrogenase ( IDH )-wild type glioblastoma to direct temozolomide therapy. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag103
Vancouver
Pittman P, Sun C, Samec T, Davidson C, Bryant D, Alnahhas I, et al. MGMTai: O6-methylguanine-DNA methyltransferase ( MGMT ) methylation prediction in isocitrate dehydrogenase ( IDH )-wild type glioblastoma to direct temozolomide therapy. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag103
BibTeX
@article{Pittman2026,
author = {Pittman, Patricia and Sun, Chen and Samec, Timothy and Davidson, Christian and Bryant, David and Alnahhas, Iyad and Glantz, Michael and Hahn-Lowry, Robert and Spetzler, David and Magee, Daniel and Nicolaides, Theodore},
title = {MGMTai: O6-methylguanine-DNA methyltransferase ( MGMT ) methylation prediction in isocitrate dehydrogenase ( IDH )-wild type glioblastoma to direct temozolomide therapy},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag103}
}
EUVIMED